Investment analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.
Evogene Stock Performance
NASDAQ EVGN opened at $0.66 on Wednesday. The company has a market capitalization of $27.15 million, a PE ratio of -1.24 and a beta of 1.49. The business’s fifty day moving average is $0.79 and its 200 day moving average is $0.74. Evogene has a fifty-two week low of $0.45 and a fifty-two week high of $1.44.
Evogene (NASDAQ:EVGN – Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. The business had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.73 million. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. During the same period last year, the firm earned ($0.07) earnings per share.
Institutional Investors Weigh In On Evogene
Evogene Company Profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Further Reading
- Five stocks we like better than Evogene
- The 3 Best Blue-Chip Stocks to Buy Now
- Hasbro’s Management Made All the Right Calls This Quarter
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How to Use the MarketBeat Excel Dividend Calculator
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.